Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?

被引：8
|
作者：
Brunner, Thomas B. [1 ,2 ]
机构：
[1] Univ Freiburg, Dept Radiat Oncol, D-79106 Freiburg, Germany
[2] Univ Oxford, Dept Oncol, Gray Inst Radiat Oncol & Biol, Oxford, England
来源：
CURRENT ONCOLOGY REPORTS | 2013年 / 15卷 / 02期
关键词：
Pancreatic cancer; Neoadjuvant chemoradiotherapy; Potentially resectable; Borderline resectable; PHASE-II TRIAL; INTRAOPERATIVE RADIATION-THERAPY; PREOPERATIVE CHEMORADIATION; RESPONSE EVALUATION; ADENOCARCINOMA; CHEMORADIOTHERAPY; CARCINOMA; OUTCOMES; PANCREATICODUODENECTOMY; CHEMOTHERAPY;
D O I：
10.1007/s11912-012-0291-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Although neoadjuvant chemoradiotherapy has been tested for more than two decades and can be safely delivered to patients with non-metastatic pancreatic cancer, no randomised trials have been reported until now. Here we provide an overview of the first randomised trial in patients with potentially resectable cancer and of the latest developments in neoadjuvant therapy for this group of patients. It is necessary to continue to perform clinical trials in this field to accurately identify the effect on survival and quality of life in patients with potentially resectable, borderline resectable and unresectable pancreatic cancer. Aspects of imaging for restaging and clinical prognostic factors are also discussed given they will be useful instruments for future trials.
引用
收藏
页码：162 / 169
页数：8
相关论文
共 50 条
  • [41] Adjuvant Therapy versus neoadjuvant Therapy for Borderline resectable Pancreatic Cancer
    Manekeller, Steffen
    [J]. ZENTRALBLATT FUR CHIRURGIE, 2018, 143 (05): : 457 - 457
  • [42] Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
    Kovtun, K.
    Moser, J. A.
    Callery, M.
    Kent, T.
    Tseng, J.
    Miksad, R.
    Bullock, A.
    Schlechter, B.
    Mahadevan, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E198 - E198
  • [43] Updates on the Use of Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
    Chandhok, Namrata Sonia
    Saif, Muhammad Wasif
    [J]. JOURNAL OF THE PANCREAS, 2014, 15 (02): : 91 - 94
  • [44] Outcome Following Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Stokes, J. B.
    Walters, D. M.
    Norris, N. J.
    Stelow, E. B.
    Rich, T. A.
    Weiss, G. R.
    De Lange, E. E.
    Adams, R. B.
    Bauer, T. W.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 : 80 - 80
  • [45] The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
    Christoph Springfeld
    John P. Neoptolemos
    [J]. Nature Reviews Clinical Oncology, 2022, 19 : 285 - 286
  • [46] Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer
    Chawla, Akhil
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (06) : 1423 - 1431
  • [47] The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
    Springfeld, Christoph
    Neoptolemos, John P.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (05) : 285 - 286
  • [48] NEOADJUVANT THERAPY VERSUS SURGERY FIRST FOR RESECTABLE PANCREATIC CANCER
    Almerey, Tariq
    Hyman, David
    Li, Zhuo
    Tice, Mary
    Porrazzo, Gina
    Stauffer, John
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1538 - S1538
  • [49] Neoadjuvant therapy in resectable pancreatic cancer-is this the way forward?
    Perri, Giampaolo
    Marchegiani, Giovanni
    Malleo, Giuseppe
    Salvia, Roberto
    [J]. CHINESE CLINICAL ONCOLOGY, 2021, 10 (05)
  • [50] Neoadjuvant therapy for resectable pancreatic cancers
    Inoue, Yosuke
    Ito, Hiromichi
    Takahashi, Yu
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 583 - 585
12345